Adefovir Dipivoxil: A Review of its Use in Chronic Hepatitis B

Drugs

Volumn 63, Issue 20, 2003, Pages 2215-2234

  Dando, Toni M ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adefovir dipivoxil; Hepatitis B; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

ADEFOVIR; ADEFOVIR DIPHOSPHATE; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOTRANSFERASE; ANTIVIRUS AGENT; COTRIMOXAZOLE; CREATININE; DRUG METABOLITE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B(E) ANTIGEN; IBUPROFEN; LAMIVUDINE; PARACETAMOL; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DNA SYNTHESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMA CELL; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LIVER DISEASE; LIVER TRANSPLANTATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT MONITORING; PRURITUS; RASH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URINARY EXCRETION; VIROLOGY; VIRUS ISOLATION; VIRUS REPLICATION; WEIGHT REDUCTION;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS;

DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0142074315     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363200-00007     Document Type: Review

References (75)

1. Delaney WE IV, Bartholomeusz A, Locarnini SA. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opinion Investig Drugs 2002; 11 (2): 169-87
2. WHO. Hepatitis B [online]. Available from URL: http:// www.who.int/inf-fs/en/fact204.html [Accessed 2003 May 26]
3. EASL Jury. EASL international consensus conference on hepatitis B: 13-14 September 2002. J Hepatol 2003; 38: 533-40
4. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol 2003; 38: S90-103
5. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24
6. Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol 2003 Jul; 13 (4): 255-72
7. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41
8. Mailliard ME, Gollan JL. Suppressing hepatitis B without resistance: so far, so good. N Engl J Med 2003; 348 (9): 808-16
9. Regev A, Schiff ER. Drug therapy for hepatitis B. Adv Intern Med 2001; 46: 107-35
10. Yuen MF, Lai C-L. Treatment of chronic hepatitis B. Lancet Infect Dis 2001 Nov; 1 (4): 232-41
11. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 2003; 23 (1): 81-8
12. Torresi I, Locarnini SA. New therapeutic strategies in the treatment of hepatitis B virus infection. Expert Opin Invest Drugs 1999 Mar; 8: 289-305
13. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000 Feb; 118 (2Suppl. 1): S83-103
14. Gilead Sciences Inc. Hepsera (adefovir dipivoxil) full prescribing information. Foster City (CA): Gilead Sciences Inc., 2002 Sep
15. Naesens L, Snoeck R, Andrei G, et al. HPMPC (cidofovir), PMEA (adefovir), and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir Chem Chemother 1997; 8: 1-23
16. Yokota T, Konno K, Shigeta S, et al. Inhibitory effects of acyclic nucleoside phosphonate analogues on hepatitis B virus DNA synthesis in HBG11 cells. Antiviral Chem Chemother 1994; 5: 57-63
17. Birkus G, Gibbs CS, Cihlar T. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J Viral Hepat 2003; 10: 10-54
18. Heijtink RA, De Wilde GA, Kruining J, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antivir Res 1993; 21: 141-53
19. Heijtink RA, Kruining J, De Wilde GA, et al. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother. 1994; 38: 2180-2
20. Kruining J, Heijtink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol 1995 Mar; 22: 263-7
21. Yokota T, Mochizuki S, Konno K, et al. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991; 35: 394-7
22. Delaney IV WE, Yang H, Miller MD, et al. Combinations of adefovir with lamivudine, entecavir or L-dT produce additive antiviral effects against HBV in vitro [abstract no. 628 + oral presentation]. 37th Annual Meeting of the European Association for the Study of the Liver; 2002 Apr 18-21; Madrid
23. Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003 Jul; 38(1): 96-103
24. Xiong S, Yang H, Westland CE, et al. Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil [plus oral presentation]. 38th Annual Meeting of the European Association for the Study of the Liver; 2003 Mar 29-Apr 1: Istanbul. J Hepatol 2003; 38 Suppl. 2: 182
25. Xiong X, Flores C, Yang H, et al. Mutations in human hepatitis B virus polymerase associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir [abstract no. 97]. Antiviral Res 1998 Mar; 37: A66
26. Xiong X, Flores C, Gibbs C, et al. Lack of cross-resistance to PMEA for human hepatitis B DNA polymerases which express lamivudine resistance codons [abstract no. 1211]. Hepatology 1997 Oct; 26 (Suppl. Pt 2): 431A
27. Xiong X, Yang H, Westland CE, et al. Human hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir [abstract no. 1313]. Hepatology 1998 Oct; 28 (Suppl. Pt 2): 491A
28. Bartholomeusz A, Littlejohn M, Ayres A, et al. Analysis of hepatitis B virus mutations in orthotopic liver transplant patients receiving sequential antiviral therapy [abstract no. 1189]. Hepatology 2000 Oct; 32 (Pt 2): 457A
29. Thibault V, Benhamou Y, Bochet M, et al. 96 weeks of adefovir dipivoxil (ADV) therapy in chronic hepatitis B patients coinfected with HIV and lamivudine-resistant (LAM-R) HBV is not associated with emergence of specific HBV polymerase mutations [abstract no. 1903]. Hepatology 2002 Oct; 36 (Pt 2): 639A
30. Boni C, Penna A, Ogg GS. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33 (4): 963-71
31. Cooksley H, Chokshi S, Wedemeyer H, et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study [abstract no. 1881]. Hepatology 2002; 36 (4 Pt 2): 633A
32. Cooksley H, Chokshi S, Wedemeyer H, et al. Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: a multicentre, controlled study [abstract no. 16 + oral presentation]. J Hepatol 2002 Apr; 36 Suppl. 1: 7
33. Kearney B, Knight W, Currie G, et al. Adefovir dipivoxil safety and pharmacokinetics in subjects with hepatitis B virus infection and in healthy subjects [abstract no. 352 + poster]. J Hepatol 2002 Apr; 36 Suppl. 1: 100
34. Kearney B, Currie G, Knight W, et al. Development and evaluation of dosing guidelines for adefovir dipivoxil in patients with chronic hepatitis B and renal impairment [abstract no. 1900]. Hepatology 2002 Oct; 36 (Pt 2): 638A
35. Knight W, Hayashi S, Benhamou Y, et al. Dosing guidelines for adefovir dipivoxil in the treatment of HBV infected patients with renal or hepatic impairment [abstract no. 631 + poster]. 37th Annual Meeting of the European Association for the Study of the Liver; 2002 Apr 18-21; Madrid
36. Hu P, Jiang J, Wang H, et al. Adefovir pharmacokinetics in healthy Chinese subjects [abstract no. 1859]. Hepatology 2002 Oct; 36 (Pt 2): 628A
37. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999 Feb; 36 (2): 127-43
38. Balzarini J, Hao Z, Herdewijn P, et al. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci 1991; 88: 1499-503
39. Data on file, Gilead Sciences Inc., 2003 Jul
40. Kearney B, Knight W, Currie G, et al. A drug-drug interaction study between adefovir dipivoxil and lamivudine, acetaminophen, ibuprofen and trimethoprim/sulfamethoxazole [abstract no. 353 + poster]. J Hepatol 2002 Apr; 36 Suppl. 1: 100
41. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 800-7
42. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 808-16
43. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract no. 845 + poster]. Hepatology 2002 Oct; 36 (Pt 2): 374A
44. Willems B, Lau G, Leung N, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52-week results [abstract no. 45 + poster]. Fourth International Workshop Therapies for Viral Hepatitis; 2002 Oct 29-31; Boston (MA)
45. Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis [abstract no. 69 + oral presentation]. J Hepatol 2003 Apr; 38 Suppl. 2: 25
46. Schiff E, Lai C-L, Neuhaus P, et al. Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre- and post-liver transplantation with lamivudine-resistant hepatitis B virus (HBV) patients [abstract no. 831 + poster], Hepatology 2002 Oct; 36 (Pt 2): 371A
47. Perrillo R, Schiff E, Hann H-WL, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine - preliminary 24 week results [abstract no. 708]. Hepatology 2001 Oct; 34 (Pt 2): 349A
48. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001 Sep 1; 358 (9283): 718-23
49. Heathcote E, Jeffers L, Perrillo R, et al. Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection [abstract no. 391]. J Hepatol 2002 Apr; 36 Suppl. 1: 110-1
50. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1 (5): 431-5
51. Data on file, Gilead Sciences Inc., 2003 Sep
52. Neumann AU, Havlin Y, Ronen T, et al. Long-term HBV kinetics classification during treatment with adefovir dipivoxil [abstract no. 644 + poster]. 37th Annual Meeting of the European Association for the Study of the Liver; 2002 Apr 18-21; Madrid
53. Westland C, Delaney W IV., Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003 Jul; 125 (1): 107-16
54. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and clinical status regardless of baseline Knodell fibrosis score in patients with HBeAg+ chronic hepatitis B [abstract no. 507]. Gastroenterology 2003 Apr; 124 Suppl. 1: A714
55. Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [abstract no. 492]. J Hepatol 2003 Apr; 38 Suppl. 2: 143
56. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil (ADV) 10 mg for the treatment of patients with HBeAg+ chronic hepatitis B: continued efficacy beyond 48 weeks. Hepatology 2002 Oct; 36 (Pt 2): 373A
57. Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B. Oral presentation presented at the 38th Annual Meeting of the European Association for the Study of the Liver; 2003 Mar 29-Apr 1; Istanbul
58. Zoulim F, Trepo C, Poynard T, et al. Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy. [abstract no. 635] J Hepatol 2003 Apr; 38 Suppl. 2: 184
59. Benhamou Y, Bochet M, Thibault V, et al. 96 week efficacy and safety of adefovir dipivoxil (ADV) for lamivudine-resistant (LAM-R) HBV in chronic hepatitis B patients co-infected with HIV [abstract no. 1902]. Hepatology 2002 Oct; 36 (Pt 2): 638A
60. Heathcote J, Chang T-T, Lim SG, et al. Safety profile of 48 weeks of adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two phase III studies [abstract no. 1882]. Hepatology 2002 Oct; 36 (Pt 2): 633A
61. Chang TT, Lim SG, Hadziyannis S, et al. Long-term safety of adefovir dipivoxil (ADV) 10mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase II studies [abstract no. 454]. J Hepatol 2003 Apr; 38 (Suppl. 2): 133
62. European Agency for Evaluation of Medicinal Products. Hepsera 10mg: Summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Aug 28]
63. Lok ASF. Hepatitis B: progress in the last decade. Semin Liver Dis 2003; 23 (1): 1-6
64. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119: 312-23
65. Liaw Y-F. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002 Dec; 17 Suppl. 3: S333-7
66. Cooksley WGE, Lai M-Y, Piratvisuth T, et al. Treatment with peginterferon alfa-2a (40kD) (pegasys) results in improved rates of response compared to conventional interferon in patients with HBeAg positive chronic hepatitis B harbouring HBV genotypes B or 'difficult-to-treat' genotype C [abstract no. 67]. J Hepatol 2003 Apr; 38 Suppl. 2: 25
67. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999 Jul; 58: 101-41
68. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002 Jul; 97 (7): 1618-28
69. Lai C-L, Dienstag J, Schiff E, et al. Prevalence and clincal correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96
70. Hepatitis B Foundation. Hepatitis B clinical trials [online]. Available from URL: http://www.hepb.org/2-00-02-0118. hepb [Accessed 2003 Jun 25]
71. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B Rm): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003; 63 (10): 1021-51
72. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs 2000 Oct; 60 (4): 701-10
73. Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol Hepatol 2002 Feb; 17 Suppl.: S125-45
74. Walsh K, Alexander GJM. Update on chronic viral hepatitis. Postgrad Med J 2001 Aug; 77 (910): 498-505
75. Ricciuti JS. Food and Drug Administration approvals [online]. Available from URL: http://www.medscape.com/viewarticle/ 442812 [Accessed 2003 Jun 25]